Study suggests convalescent plasma does not prevent COVID-19
A recent study suggests convalescent plasma does not prevent COVID-19. It is a common therapy for inpatients with COVID-19. The approach is based on the use of antibodies from recovered patients to help other patients with the disease. The FDA will review this data and more study data to comment and provide guidance on the use of convalescent plasma.
An independent committee found there was no clear benefit for patients. Consequently, the NIH halted a clinical trial. A new trial is aiming to treat 900 patients to better understand what outcomes can be expected with this therapy. Another group focused on safety recently indicated that there was no obvious benefit for patients. The research group will further analyze more data before expressing their conclusions on this treatment.
Dr. Simone Glynn, the NIH trial’s program scientist, stated the following: “we do not see any sign that convalescent plasma had a benefit” for at risk in patients that can become more ill.
Daniel Griffin, infectious disease specialist at New York’s ProHEALTH Care, provided further comment: “convalescent plasma, in the setting of COVID-19, doesn’t seem to provide a significant impact on mortality and hospitalization rates, two key metrics looked at during the trial.”
More than 180 clinical trials are testing the efficacy and safety of convalescent plasma for COVID-19. Johns Hopkins University is investigating whether the therapy lowers the risk of symptoms in people that had exposure to SARS-CoV-2 in 2 studies. Another trial aims to assess if plasma may help hospitalized individuals at the start of their disease.
More research will eventually show data to offer more conclusive understanding and guidance on the use of convalescent plasma for patients with COVID-19.
Watch this space for more developments in therapeutics.
Our Editorial Note: Contact us if you would like to learn more about regenerative medicine and how it may help patients with Covid-19 and other medical conditions.